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Introduction Hospital-acquired infections are a frequent and serious public health problem. 
More than 60% of intensive care unit patients with Staphylococcus aureus have a methicillin-
resistant form. Active surveillance cultures (ASCs), which are universal or targeted screening 
cultures of patients admitted to a hospital unit, have been proposed to control the increasing 
numbers of infections caused by multi-drug resistant organisms. Infection control groups and 
policy makers have an interest in ASCs, but this method is controversial because it is unclear if it 
reduces morbidity and mortality and if it is cost-effective. 
Methods A systematic review of the literature pertaining to the use of ASCs and control of 
methicillin-resistant Staphylococcus aureus (MRSA) was conducted. The literature search 
included PubMed MEDLINE (1966- present), Web of Science (1955- present), CINAHL (1982 
-present), the Cochrane Library, and a hand search of six infection control journals from 2000-
2007 and the reference lists of the included articles. Two independent reviewers selected the 
primary research studies to be included. Included articles were summarized and assigned quality 
ratings. 
Results Sixteen observational studies and four economic analyses were included in this 
systematic review. Only two of the sixteen (12.5%) observational studies had a control group. 
None of the studies were of high quality. No randomized controlled trials were identified. 
Discussion This review identified many gaps within the literature, including a need for a clear 
definition of ASCs, a clear implementation protocol that includes a defined screening group and 
laboratory methods, and rigorous economic evaluations. Existing evidence favors the use of 




Purpose of the Master's Paper 
Hospital-acquired infections are a frequent and serious public health problem, and their 
management and control are essential to minimize hospital-related morbidity and mortality.1 
Some of the most challenging causes of hospital-acquired infections involve multi-drug resistant 
organisms, including methicillin-resistant Staphylococcus aureus (MRSA). 1' 2 There are 
numerous infection control methods that hospitals and other health care facilities employ; 
however, increasing numbers of infections are caused by multi-drug resistant organisms. One 
possible infection control measure is active surveillance culturing of patients admitted to 
hospitals or other health care facilities. However, there is not a clear definition of what 
constitutes an "active surveillance culture" and how it should be used. There is also controversy 
in the field about the importance of active surveillance cultures in infection control. 
This Master's paper is a systematic review of the effectiveness of active surveillance 
cultures to decrease hospital-acquired MRSA. National guidelines, existing reviews, and 
original research will be reviewed, and clinical recommendations from a national health care 
improvement campaign will be evaluated. Current evidence on the ability of active surveillance 
cultures to decrease MRSA-related morbidity and mortality, and on the cost-effectiveness of 
active surveillance culture programs, will be summarized. 
History of Methicillin-Resistant Staphylococcus aureus (MRSA) 
Drug resistant organisms have been recognized as a problem for decades. In 1943, only 
four years after penicillin became widely used, the first strains of penicillin resistant 
Staphylococcus aureus were isolated? Resistant bacteria were able to produce penicillinase, an 
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enzyme that renders that antibiotic inactive. Since that time, bacteria have continued to evolve 
ways to evade the action of penicillin and over 200 types of penicillinases have been discovered.4 
As the bacteria have evolved, there have also been advances in the pharmacology of antibiotics 
that have allowed physicians and infection control officers to maintain effective infection 
treatment and control. An example of one such advance in 1960 is methicillin; however, like its 
older counterpart, penicillin, Staphylococcus aureus soon developed resistance to the drug. The 
first isolates of methicillin-resistant Staphylococcus aureus (MRSA) were discovered in the 
United Kingdom just six months after the introduction of the drug.5 The first cases ofMRSA in 
the United States occurred in 1968_2 Thirty years later, in 1999, slightly over 50% of the 
Staphylococcus aureus isolates taken from patients in intensive care units (ICUs) in the United 
States were resistant to methicillin? The resistance problem has continued to grow and now over 
60% ofiCU patients with Staphylococcus aureus have MRSA.2 (Figure I) 
Methicillin (oxacillin)-resistant Staphylococcus 
aureus among ICU patients, 1995-2004 
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Figure 1. Methicillin-resistant strains of Staphylococcus aureus have increased in the 
United States over the last 12 years. Source: National Nosocomial Infections 
Surveillance (NNIS) System6 
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Researchers have been able to determine that methicillin-sensitive Staphylococcal aureus 
(MSSA) becomes resistant when it acquires a large genetic element called staphylococcal 
cassette chromosome mec (SCCmec).4 Genetic analysis ofMRSA isolates from a variety of 
locations throughout the world indicate that SCCmec has only been transferred from a MRSA 
strain to a MSSA strain a few times; therefore, worldwide, there are only a few clonal types of 
MRS A. 4• 5 This implies that MRSA does not evolve from random de novo mutations within an 
individual colonized with MSSA. 4 Instead, patients with MRSA colonization or infection most 
likely have acquired it from coming into contact with drug resistant bacteria. Therefore, 
preventing MRSA exposure and transmission are key in the control of the drug resistant 
organism. 
Nosocomial Infections: A Public Health Problem 
As a combined group, infectious diseases are the third leading cause of death in adults in 
the United States behind heart disease and cancer.4 Unfortunately, a percentage of these 
infections are acquired in hospitals. Infections are considered to be hospital-acquired, or 
nosocomial, if they appear after two days of hospitalization or within thirty days after discharge.7 
Excluding other types of healthcare facilities, in hospitals alone there are approximately 2 
million nosocomial infections per year in the United States.8 Because many hospital-acquired 
infections emerge as complications of an underlying disorder or procedure, it is hard to 
determine exactly how much morbidity and mortality they cause; however, it is clear that the 
presence of microorganisms in hospitals does contribute to overall increases in morbidity, 
mortality, and healthcare costs.5 One estimate suggests that nosocomial infections could be 
responsible for 90,000 deaths per year in the United States. 8 
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MRSA Control Measures 
As a nosocomial or hospital-acquired infection, MRSA presents a significant burden to 
the United States healthcare system. Although it is now possible to be infected with community-
acquired strains ofMRSA, the majority ofMRSA infections are still acquired in healthcare 
facilities. Accordingly, there have been many attempted interventions to reduce MRSA infection 
rates. To spread an infection, there must be 1) a source, 2) a mode of transmission, and 3) a 
susceptible new host. In hospitals, it is difficult to control source populations and susceptible 
new hosts, so most infection control measures are aimed at interrupting the transmission of 
pathogens.9 
Thorough hand washing is commonly cited as the most important intervention for 
controlling spread of infection from one patient to another. 9 In addition to hand washing, the 
Centers for Disease Control and Prevention (CDC) also recommends that patients infected with 
certain microorganisms are assigned to a single room, transported as infrequently as possible, 
and have specific or individualized patient care equipment available in the room.9 In certain 
cases, gloves, protective gowns, and masks may be required.9 
The Hospital Infection Control Practices Advisory Committee (HICPAC), in conjunction 
with the CDC, have also defined two tiers of isolation precautions to prevent the transmission of 
microorganisms.9 The first tier is called "standard precautions" and it applies to all hospitalized 
patients and includes using gloves and/or other effective barriers when handling blood, bodily 
secretions, mucous membranes, or nonintact skin. The second tier is called transmission-based 
precautions and it includes three divisions: airborne precautions, droplet precautions, and contact 
precautions. These transmission-based precautions are used for patients who have a documented 
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infection. 9 MRSA is primarily spread through direct or indirect contact, so patients infected with 
MRSA must be placed on contact precautions.9 When a patient is on contact precautions, 
anyone interacting with the patient must use patient-specific equipment if possible and wear 
protective gowns and gloves. Masks or respiratory barriers are not needed.9 
In 2003, the Society for Healthcare Epidemiology of America (SHEA) published a 
special report titled "SHEA Guideline for Preventing Nosocomial Transmission ofMultidrug-
Resistant Strains of Staphylococcus aureus and Enterococcus. "4 The guideline was 
commissioned because the organization felt it was not making progress with reducing the 
number of hospital-acquired infections despite it being a priority.4 The recommendations put 
forth in the SHEA guideline were not based on a systematic review. 
Instead, recommendations stemmed from evidence found in literature published on PubMed 
MEDLINE (1966-2002, unreported search strategy) and unpublished literature in the authors' 
libraries. The major recommendations of the guideline involve using active surveillance 
cultures to identify the reservoir from which MRSA can spread, limiting unnecessary antibiotic 
use to reduce the risk of more bacteria developing drug resistance, and increasing hand hygiene, 
barrier precautions, and decolonization of colonized patients to limit opportunities for 
• • 4 transmiSSIOn. 
The 2003 SHEA guideline was the first time that a major infection control organization 
strongly recommended the use of active surveillance cultures and it created controversy within 
the field. 10 Despite the controversy, other groups and policy makers seemed to take interest in 
active surveillance cultures as a new approach to improving infection control. One such 
organization is the Institute for Healthcare Improvement (IHI). 
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Institute for Health care Improvement: The 5 Million Lives Campaign 
The IHI is a non-profit organization that was founded in 1991 to "improve the lives of 
patients, the health of communities, and the joy of the healthcare workforce."11 The IHI 
launched the 5 Million Lives Campaign in December 2006 with a mission to "protect patients 
from five million incidents of medical harm over the next two years [Dec 2006- Dec 2008]."12 
The organization defmes medical harm as: 
"Unintended physical injury resulting from or contributed to by 
medical care (including the absence of indicated medical treatment), 
that requires additional monitoring, treatment or hospitalization, or that 
results in death. Such injury is considered harm whether or not it is 
considered preventable, resulted from a medical error, or occurred 
within a hospital. "12 
In order to substantially reduce medical harm, the campaign managers hope to enlist 
4,000 hospitals in the United States to work on quality improvement in eleven different focus 
areas. These focus areas are: improve rapid response teams, provide evidence-based care for 
acute myocardial infarction, provide evidence-based care for congestive heart failure, prevent 
adverse drug events, prevent harm from high-alert medications, reduce surgical complications, 
prevent pressure ulcers, prevent central line infections, prevent surgical site infections, prevent 
ventilator associated pneumonia, and reduce MRSA infection rates. 12 
Many of the 5 Million Lives Campaign's goals are concentrated on the morbidity and 
mortality related to nosocomial infections. Of their infection control goals, reducing MRSA 
infection rates may be one of the most significant because MRSA is often the bacterium isolated 
from central line infections, surgical site infections, and ventilator associated pneumonia. By 
achieving the goal of MRSA infection reduction, it is likely that it will be easier to meet other 
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infection-specific goals. The IHI recommends using a five-pronged approach to reduce MRSA 
infections that includes: 
1. Hand hygiene 
2. Active surveillance cultures 
3. Isolation precautions 
4. Improved environmental services cleaning 
5. Ventilator and central line bundling 
Active surveillance cultures are the focus of this Master's Paper since this intervention is 
relatively new, controversial, and not conclusively shown to be successful or cost-effective over 
time. 
Active Surveillance Cultures (ASCs) 
Colonized and infected patients, not environmental contamination, represent the largest 
reservoir ofMRSA in health-care facilities. 5• 13 At many institutions, only patients with 
infection-like symptoms have microbiological samples taken to be cultured to assist with the 
diagnosis of active MRSA infection. While this effectively identifies infected patients who need 
immediate treatment, it does not address asymptomatic, colonized patients who represent the 
other portion of the pathogen reservoir. It has been estimated that 35-84% of colonized patients 
go undetected by clinical culturing of only symptomatic patients.5 Using active surveillance 
cultures (ASCs), or universally screening all patients admitted to a unit by culturing 
microbiological samples taken from the anterior nares, will identify 80% of patients colonized 
withMRSA.5 
Identifying all of the colonized patients is only the first step in eliminating the reservoir 
ofMRSA. The knowledge gained from active surveillance cultures is only helpful in reducing 
cross contamination if it helps hospital staff use appropriate contact and hygiene measures. As 
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MRSA carriers are identified, they can be treated in a manner similar to other patients with 
active MRSA infections. By isolating colonized patients and putting them on contact 
precautions, health care workers theoretically will be more likely to adhere to strict hygiene 
measures and less likely to spread the infection to other patients. Further, colonized patients can 
be decolonized to eradicate the MRSA with a fairly simple treatment regimen involving 
chlorhexidine gluconate for washing, topical intranasal mupirocin, and/or oral rifampin and 
doxycycline for seven days.14 
Although identifying patients who act as a reservoir ofMRSA and then managing them 
accordingly intuitively seems like a good idea, there is a great amount of controversy 
surrounding the concept of active surveillance cultures. A survey of 463 infectious disease 
specialists indicates that there is little agreement on the subject. 15 The study showed that only 
50% of the specialists were in favor of using active surveillance cultures (ASCs), and only 30% 
worked in healthcare facilities that routinely used ASCs. The half of the respondents who 
oppose universal MRSA screening cite the following reasons: 
"First, need additional laboratory resources and are costly; second, create 
increased demand for isolation rooms; third, could cause logistic 
difficulties when newly identified patients are moved from one room to 
another; and fourth, could delay placement of some patients into extended-
care facilities. Additionally, the effectiveness of screening cultures to 
reduce transmission of MRSA has not been established in randomised 
trials."15 
To further complicate matters, there is not a standard definition of what constitutes an 
"active surveillance culture." It is unclear what population should be screened for MRSA 
colonization. Possible options would be to screen all patients admitted to the hospital or only 
"high-risk" patients, which could include patients being readmitted, admitted to an ICU, or 
transferred from another hospital or long term care facility as well as patients with certain 
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medical conditions. It is also unclear how isolation precautions should be used in conjunction 
with ASCs. One option is that all of the patients in the chosen screening population should be 
put on isolation precautions until it is proven that they are negative for MRSA, but another 
option is that patients should they be put on precautions only after it is shown that they are 
positive for MRS A. The frequency of screening is not defined either, and there does not appear 
to be much understanding of how soon after admission a previously negative patient can become 
colonized and how often follow up cultures should be performed to expeditiously identify these 
newly converted patients. 
SHEA and the IHI, among other professional organizations, actively support ASCs as a 
part of their campaign to eliminate MRSA infections; however, hospitals have been left to decide 
for themselves exactly what should be done and how ASCs should be incorporated into their 
infection control protocols. 
Focused question 
Professional organizations and infection control officers agree .that hospital-acquired 
infections must be prevented, but do not agree on the most effective method of prevention. In 
adult medical and surgical intensive care units, are active surveillance cultures (compared to no 
screening cultures or usual care) associated with MRSA-related mortality, incidence ofMRSA 
infections (bacteremia, cellulitis, abscess), or cost ofMRSA-related care? 
13 
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Defining the question 
Population= patients in adult surgical or medical intensive care units 
Intervention = active surveillance culture 
McGinigle 
Comparison= no surveillance cultures or usual care (ie, screening only high-risk patients) 
Outcome= MRSA-related mortality, incidence ofMRSA infections, cost ofMRSA-related care 
This systematic review addresses only patients in intensive care units because these units 
have been shown to be the most likely location for the cross transmission and acquisition of 
nosocomial infections that are resistant antimicrobial drugs. 16 The intervention to be evaluated is 
nasal swabs for culture ofMRSA that occur at admission to the ICU and at least weekly 
thereafter because nasal swabs alone have been shown to identify 80% of MRSA carriers, which 
is more than any other body site.12 However, studies that collect culture specimens from other 
body sites in addition to the anterior nares at least weekly will also be included. The comparison 
group is defined as a group that does not receive weekly cultures from the nares for MRSA 
detection or a group that receives usual care (ie, comparison of screening only high-risk patients 
vs. universal screening). The outcomes are limited to MRSA-related mortality, incidence of 
MRSA infections, and cost ofMRSA-related care. 
Search strategy 
To maximize the sensitivity of the search, articles were gathered from a wide variety of 
sources. The following search strategies were used in PubMed MEDLINE (1966- present), Web 
of Science (1955 -present), CINAHL (1982 -present), and the Cochrane Library: 
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("Methicillin Resistance"[Majr] OR "methicillin resistant"[tw] OR "methicillin 
resistance"[tw]) AND ("Staphylococcal Infections"[Majr] OR "Staphylococcus 
aureus"[Majr] OR (mrsa[tw] NOT medline[sb])) AND ("sentinel 
surveillance"[ mesh] OR surveillance[tw] OR "Mass Screening"[mesh] OR 
screening[tw] OR active screening[tw] OR active surveillance[tw]) 
("Methicillin Resistance"[Majr] OR "methicillin resistant"[tw] OR "methicillin 
resistance"[tw]) AND ("Staphylococcal Infections"[Majr] OR "Staphylococcus 
aureus"[Majr] OR (mrsa[tw] NOT medline[sb])) AND ("economics"[Subheading] 
OR "costs and cost analysis"[MeSH Terms] OR cost[Text Word]) 
List of search terms: 
1. methicillin resistance 8. mass screemng 
2. methicillin resistant 9. screening 
3. Staphylococcal infections 10. active screening 
4. Staphylococcus aureus 11. active surveillance 
5. MRSA 12. economics 
6. sentinel surveillance 13. costs and cost analysis 
7. surveillance 14. cost 
Also, a hand search of the Centers for Disease Control and Prevention and Institute for 
Healthcare Improvement websites was completed to look for guidelines and cited original 
articles. Six of the major journals in the field of infection control were also hand searched from 
2000-2007. These journals are Journal oflnfectious Disease, Clinical Infectious Diseases, 
Journal of Hospital Infection, Infection Control and Hospital Epidemiology, and the American 
Journal oflnfection Control. Finally, the reference lists of included articles were hand searched. 
Personal communication with David Weber, MD, MPH, an expert in the field of hospital 
infection control, confirmed the inclusiveness of the overall search strategy.17 
Eligibility criteria 
The study population was limited to patients in intensive care units who were screened 
for MRSA at admission and at least weekly thereafter. After an exploratory search of the 
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literature, these parameters seemed to be the most commonly used and have a certain degree of 
. 'fi . b hi d h 12 16 18 F rth h . h . sc1ent1 1c reasonmg e n t em. · · u er, t e pnmary outcomes c osen were patient 
centered (ie, MRSA infection rates, MRSA-related mortality, or all cause mortality) or related to 
cost-benefit. 
The body of literature regarding active surveillance cultures includes few studies with 
rigorous study designs; therefore, broad criteria for study designs that could be included were set. 
More emphasis was placed on studies that were well designed with appropriate control groups, 
but uncontrolled before-and-after studies and ecological studies were also included to cover the 
literature upon which current recommendations have been made (Table I). 
Table 1. Eligibility criteria. 
Inclusion Criteria Exclusion Criteria 
Adult medical or surgical ICU patients All non-ICU patients, and all Neonatal ICU or 
Pediatric ICU patients 
Measurement of hospital-acquired drug Measurement of community-acquired S. aureus 
resistant Staphylococcal aureus (including or pathogens other than S. aureus 
methicillin, oxacillin, etc) 
At least weekly nasopharyngeal cultures from Less frequent or unscheduled nasopharyngeal 
all ICU patients in intervention group cultures or culturing only targeted patients 
Comparison group similar to intervention Lack of a comparison group or control group 
group, but not receiving screening 
nasopharyngeal cultures 
Primary outcomes: MRSA-related mortality, Primary outcomes unrelated to MRSA patient 
infection, or costs outcomes or costs 
Experimental study design (ie, RCT), quasi- Cross sectional studies, case series, case 
experimental design (ie, nonrandomized trial), reports, expert opinion, reviews 
controlled observational design (ie, cohort 
studies, case-control studies, time series), 
uncontrolled before and after study design, or 
ecological studies 
English language Non-English language 
16 
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Selection of eligible articles 
First, the titles and abstracts generated by searching were subjected to the 
inclusion/exclusion criteria. Any article with an abstract that failed to meet any inclusion criteria 
or that was clearly out of the scope of the review question was excluded. The articles with 
abstracts that fully or partially fulfilled the inclusion criteria were saved and their full text copies 
were obtained. The inclusion/exclusion criteria were applied again, this time to the full text 
articles. In order to be selected, studies had to fulfill all of the inclusion criteria and none of the 
exclusion criteria. 
The judgments about which studies to include were made first by the author. Next, a 
second reviewer repeated the process starting with the abstracts and then using the full text 
articles, to reapply the inclusion/exclusion criteria to all of the articles excluded by the author. 
Any disagreements were resolved by discussion or by using a third reviewer. 
The initial search yielded 2578 articles. Either on the basis of title/abstract or full text 
review, there were 2558 articles that did not meet all inclusion criteria and were excluded from 
the review. Twenty articles were included in the review. A full QUORUM tree illustrates the 
process used to arrive at the studies finally included (Figure 2). 
17 
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Potentially relevant citations 
identified after complete 
citation/abstract search 
n = 2578 
Citation/abstracts 
excluded because they 
were out of scope 
n = 2411 
Articles included for more 
detailed application of 
inclusion criteria 
n= 167 
Articles excluded (after 
full text review) because 
they did not fit all 
inclusion criteria -
n= 147 
Relevant articles included 
in the systematic review 
n=20 
Figure 2. QUORUM tree of articles selected for systematic review. 
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Quality Assessment and Validity 
The quality criteria used to assess the internal validity of each of the included 
observational studies were based on the guidelines set forth by the United Kingdom's National 
Health Service Centre of Reviews and Dissemination (Appendix A). 19 Each study was evaluated 
in terms of the research question( s ), description of source and study population characteristics, 
intervention integrity, data collection and measurement, and analysis methods including 
adequacy of sample size and statistical methods. It is important to note that specific outcomes 
and the magnitude of effect of the intervention are separate issues from the quality of the data, 
and are not included in the quality assessment of each study. 
The quality of the economic analyses was rated based on guidelines from the United 
States Preventive Services Task Force (Appendix A).20 Each study was evaluated in terms of the 
research question, appropriateness of the study population and the reference comparison, quality 
of the effectiveness evidence on which the cost analysis is based, method used to estimate costs, 
consideration of societal costs, long term costs, and the cost of harms, and statistical methods. 
A checklist of items for each type of study design was created and used to rate the 
internal validity (ie, case selection, measurement, confounding, and statistical analyses) and 
external validity (ie, study population, interventions, and outcomes). The overall rating of 
methodological quality was based on consideration of study design, and the internal and external 
validity assessments. The quality assessment was performed by one reviewer who was not 
masked to the names of the authors, institutions, or journals. 
Observational studies that used control groups and economic analyses could be rated as 
high, moderate, or low based on the quality criteria checklist that corresponded to their study 
designs. It is mandatory that highly ranked observational studies have a control group. 
19 
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Controlled observational studies or economic analysis that satisfied 80% of the criteria on the 
checklist were rated "high", studies that satisfied 40-79% of the criteria were rated "moderate", 
and studies satisfying fewer than 40% of the criteria were rated "low". 
The same quality criteria checklists were applied to each of the uncontrolled studies in 
the same manner as the controlled studies, but the scoring system was slightly different. 
Observational studies that did not have control groups, even if well done, could not be rated as 
"high" because uncontrolled studies are subject too many possible threats to validity. Therefore, 
uncontrolled observational studies satisfying 80% of the criteria were rated "moderate" and 
studies satisfying fewer than 80% of the criteria were rated "low". 
Data Abstraction 
Studies that met all inclusion criteria were summarized and organized into an evidence 
table. All data were organized according to methodological quality rating and publication year 
with the economic analyses in a separate group at the end. The endemic level and/or importation 
rate ofMRSA in the hospitals at which the studies were being carried out were also considered. 
Although this paper does not focus on the method of culturing the samples taken for ASC, the 
use of rapid PCR versus standard culturing techniques was noted because methods vary greatly 
between hospitals and time lag before MRSA identification has implications for the use of 
isolation precautions and chance of cross-contamination. The categories in the evidence tables 
are: author and year, study design, location, sample characteristics (including prevalence of 





Twenty studies that examined active surveillance cultures and incidence of hospital-
acquired MRSA or MRSA associated costs fulfilled the criteria to be included in this systematic 
review. There were no randomized controlled trials that include patient-related outcomes of 
ASCs. Only two out of sixteen observational studies (12.5%) had a control group. There was 
one retrospective cohort study, one case-control study with a cost-effectiveness analysis, five 
interrupted time series studies, four uncontrolled before and after studies (one of which included 
a cost effectiveness analysis), five ecological studies, and four economic analyses. 
None of the studies included in this systematic review were of high quality. The two 
controlled studies had the best internal validity; however, they were still limited by weak study 
designs and other threats to validity. The maximum rating that uncontrolled studies could obtain 
was moderate due to the inherent weaknesses in the study designs. Three of the five interrupted 
time series were well done considering the limitations of the study design and got a moderate 
quality rating. All of the before and after studies and ecological studies were of low quality 
(Table 2). 
Table 2. Methodological quality by study design. 
Study Design High Quality, n Moderate Quality, n Low Quality, n 
Retrospective Cohort -- 1"' --
Study 
Case-Control Study -- t'" --
Economic Analysis -- 2"'·"" 2"'·"" 
Interrupted Time -- 3"'""' 2'"· jj 
Series Study 
Before and After -- -- 4JNJ 
Study 




A summary of all included studies can be found in an evidence table (Appendix B). 
Specific information highlighting significant results and the critical appraisal of the included 
studies follows. 
Chaix and colleagues did a case-control study in 1999, which is an observational study 
that warrants considerable attention in this systematic review because it is one of the only studies 
with a control group and it met most methodological standards.22 The cases and controls were 
selected properly and were comparable with respect to identified possible confounders, the 
intervention and measurement of outcomes was the same in both groups, and there was an 
appropriate statistical analysis. However, case-control studies are subject to considerable 
confounding, which threatens the overall internal validity and is the primary reason for the 
"moderate" quality rating. The cases in this study were adult medical ICU patients with MRSA 
infections who were randomly selected from an infection control database, and the matched 
controls were medical ICU patients who did not acquire MRSA. Over a four year period in their 
hospital, MRSA infection incidence decreased from 5.6 to 1.4 cases per 100 admissions. They 
also calculated that an ASC program is cost-effective if MRSA importation rates are between 1% 
and 7%?2 
The three interrupted time series of moderate quality were all in agreement that an ASC 
program will decrease the incidence of hospital-acquired MRSA infections. Huang et al reported 
the most striking results; a 75% decrease in MRSA infections in the ICU where the ASC 
program was being used, and a 40% decrease in MRSA infections in the remainder of the 
hospital that was not receiving the intervention.29 Wemitz et al report a 48% decrease in 
infection incidence, and Gould et al report an 11% decrease.28• 41 Despite the limitations of the 
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study design, all three of these studies were well done and their results should be seriously 
considered. They each included good measurements of baseline characteristics, evidence that the 
ASC intervention was independent of other interventions, discussion of possible confounders, 
comparisons to secular trends, and other appropriate statistical analysis. 
Three of the four economic evaluations agree that some form of ASCs and the subsequent 
management of colonized patients are cost effective. But, only two analyses, Wernitz et al and 
Lucet et al, are true cost-benefit analyses with reasonable internal validity and study designs.23• 24 
These two studies identified all relevant costs and valued them appropriately, included 
comparisons to alternative interventions, and performed a sensitivity analysis. The primary 
weakness in both studies is that they base their effectiveness evaluations on trials they have 
performed rather than on a collection of the best available evidence. Lucet et al performed a cost 
effectiveness analysis based upon a multicenter ecological study. The analysis by Wernitz et al 
is based upon an interrupted time series study, and is the best cost-effectiveness evidence 
included in this study. 
Wernitz et al reported in 2005 that their hospital was only compensated for 26% of costs 
required to care for MRSA patients who exceeded their diagnosis related group (DRG) length of 
stay and payment threshold value as a result of a MRSA infection. Using a high-risk screening 
program in their hospital, they were able to prevent about 35 cases ofMRSA infection, including 
surgical site infections, pneumonia, and blood stream infections, and estimated that their 
program saved the hospital 110,236 euros annually.23 The uncompensated costs of caring for 
MRSA patients was high (8044 euros per patient), and they calculated that only three cases of 




Lucet and colleagues were the only group who studied the costs of universal screening of 
all patients admitted to an ICU.24 In their cost-benefit analysis of moderate quality, they strongly 
support universal ASCs as they found using high-risk profiles for selective screening not 
sensitive enough to detect enough MRSA cases, and that universal screening was the most 
beneficial and cost-effective in their hospital. Using a sensitivity analysis, the determined that 
universal screening and preventive isolation saved money when the prevalence of MRSA 
colonization was between 2% and 20%.24 
The other two economic evaluations were cost comparison studies and received low 
quality ratings. Cost comparison studies are weak because they only assess the cost and not the 
effectiveness of an intervention.19 Neither of the following studies are fatally flawed because 
they did include most relevant costs and valued them appropriately; however, there is no 
consideration of alternative interventions, no measure of effectiveness, and no sensitivity 
analysis. 
Gavalda and colleagues used a cost comparison between the costs of a high-risk 
screening program and the attributable costs ofMRSA infections. Similar to the findings by 
Wernitz eta/, they reported that a high-risk screening program is cost effective iffour MRSA 
cases are prevented. In their hospital, that meant reducing incidence of infections by 11 %.Z6 
The fourth economic study, a cost comparison by Kim eta/ in 2001, was in disagreement 
with the others. They were wary of recommending ASCs because they found that screening and 
the subsequent management of colonized patients accounted for 45% of the total MRSA-related 
costs in their hospital.25 
The remainder of the included observational studies also have low internal validity, and 
their results should not contribute greatly to the conclusions drawn from this review. Seven of 
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the ten low quality studies are in agreement with the relatively higher quality studies mentioned 
above, and state that ASCs are effective in reducing the number of hospital-acquired MRSA 
infections. Eveillard and colleagues only found a decrease from 10% to 9% acquisition of 
MRSA per 100 days with ASC ofiCU patients only.32 But, when they included ICU patients, 
other high-risk patients, and an alert system in the intervention there was an overall 58% 
decrease in MRSA infections from 10.4% to 3.1% MRSA acquisition per 100 hospitalization 
days ofMRSA carriers.32 The articles by Shitrit et al, Pan eta!, and Souweine eta! all report 
about a 50% decrease in MRSA infection incidence. 30• 33• 35 Souweine and collegues also report 
that although infection rate decreased with the ASCs, there was no change in the rate ofMRSA-
related mortality.35 Tomic eta! report a dramatic decrease in incidence ofMRSA infections 
from 4.0 to 0.4 cases per 1000 patient-days (50% to 6.1% acquisition)34 Lucet and colleagues 
report a more moderate decrease from a 7.0% to a 2.8% MRSA infection incidence.37 Troche 
and colleagues found an initial decline in MRSA infection incidence from 9.2 to 6.6 cases per 
1000 patient-days, but then ASC compliance dropped to only 68% and the infection rate 
increased to 11.6 cases per 1000 patient-days. By the end of the study period, compliance had 
improved and there was a decrease in MRSA acquisition rate to 5.6 cases per 1000 patient-
days?9 
Three low quality studies report negative findings. The study by West and colleagues 
included two hospitals.31 In one hospital, the incidence of MRS A infections decreased from 0.76 
to 0.45 cases per I 000 admissions. However, at the other hospital, there was no change in the 
infection rate after implementing ASCs.31 Thompson et al also report negative findings and do 
not support ASCs because the incidence ofMRSA infections remained 5% over the course of 
their study.40 Nijssen eta! specifically separated the surveillance cultures from other subsequent 
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patient management like contact isolations, and performed daily ASCs on patients an adult 
medical ICU without reporting the results to hospital staff or using isolation. 38 Over a three 
month period, the mean daily prevalence of MRSA was about l 0%, which did not show a 
changing trend for MRSA colonization or infection compared to a three year period surrounding 
the study. Further, there was no cross-contamination ofMSSA or MRSA between ICU patients, 
and the authors conclude that had the ASC program been followed up with isolation precautions 
they would have appeared falsely successful and are not a useful infection control strategy. 38 
The results of the poor quality studies may be used to support results from better studies; 
however, without a control group, or at least trend data that have been statistically adjusted for 
serial autocorrelation and secular trends, all of the low quality studies are at risk for 
contamination of the intervention, measurement bias, and confounding. The threats to validity 





Based on the five moderate quality observational studies and the two cost-benefit 
analyses, the results show that ASCs are associated with a decreased incidence of hospital-
acquired MRSA infections and that ASCs are cost-effective under a wide variety of conditions. 
However, the lack of high quality evidence and predominance of generally mediocre studies 
must be taken into account and may introduce doubt to the overall positive results. 
Concerns about study design and confounders 
There were only two studies with control groups found in the literature. These studies 
were done well and have few threats to their validity. Their results should be emphasized over 
the results of the remaining fourteen uncontrolled observational studies included in this 
systematic review. However, although these two were the best methodologically in this review, 
prospective cohorts and randomized controlled trials are significantly stronger and more valid 
study designs.42 Unfortunately, most of the studies in this review and those that have also been 
used as evidence for guidelines are subject to confounding and have other problems inherent to 
their study designs. 
Only two of the articles reported using a control group,21 •22 and none of the studies used 
randomly assigned controls, so the possibility of confounding is great. A few potential 
confounders could be compliance with taking swabs for culture, compliance with isolation 
precautions, length of time before culture results are reported, patient length of stay, patient case 
mix, staffing levels and staff workload, use of prophylactic antibiotics, and the endemic level of 
community-acquired MRSA colonization and infection. 
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Ecological study designs are fraught with weaknesses. The ecological studies included in 
this review analyzed a population at different points in time once the ASC intervention was 
started. 36•40 The unit of analysis is the population of patients, not the individual; therefore, 
ecological studies lack the necessary linkage between individual patients and outcomes. This 
potential threat to the validity is termed "ecological fallacy," which is defined as incorrectly 
assuming that relationships found in aggregate data will also be found among individuals.43 
Additionally, without a control group for comparison, it is impossible to determine whether the 
measured outcomes are associated with or caused by the intervention. Ecological studies are of 
low quality and any conclusions drawn from them must be critically appraised and considered 
with great reservation. 
Uncontrolled before and after studies can be effective for demonstrating a change in the 
incidence rate of the outcomes, but without a control group or at least trend data (as used in 
interrupted time series) it is impossible to tell if the intervention caused the observed change. 
Although statistical significance tests can be applied to help rule out random chance causing the 
change in outcomes, there are still many confounders that could be present in the before or after 
period that cause differential bias and effect the results. Large differences in outcomes between 
the pre- and post-intervention periods may be indicative of some effect, but there cannot be 
certainty in the conclusions drawn from this kind of evidence. 
Additionally, in uncontrolled before and after studies, when a hospital unit starts the 
intervention and begins actively screening for MRSA, the detection rate increases; therefore, the 
apparent MRSA prevalence increases although true prevalence remains the same initially. The 
number ofMRSA cases cannot be used as a common denominator to compare the frequency of 
MRSA colonization before and after the intervention, so it is impossible to know how the 
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pathogen reservoir and endemic level of MRSA are changing. However, it is still possible to 
measnre and compare the incidence of overt MRSA infections as long as the diagnoses are made 
from clinical cultnres and constellations of symptoms rather than the active surveillance cultnres 
in the study intervention. 
The Role of a Randomized, Controlled Trial (RCT) 
Many infection control specialists, epidemiologists, and methodologists have called for a 
randomized controlled trial (RCT) in order to obtain reliable results and stronger guidance.44 It 
is possible that a large, multicenter RCT that uses hospitals as the unit of analysis could be very 
useful in answering many questions regarding the effectiveness of ASCs in infection control. If 
the RCT demonstrates a positive relationship and confirms the results from the weaker studies 
discussed above, then the next steps are clear. As suggested by the SHEA guideline, the hospital 
infection control departments will begin to implement some version of ASCs in their ICUs and 
other high-risk units. The result will potentially be a reduction in the MRSA infection rates and 
decreased levels of preventable morbidity and mortality. 
However, if the RCT has a negative result and finds that ASCs do not cause a decrease in 
MRSA-related morbidity, mortality, and costs, the steps to be taken will not be so obvious. Do 
the results of one highly valid study outweigh the results of many less valid studies? It is unclear 
what would happen in this situation, but it is likely that the controversy would become more 
heated. Many who have been calling for an RCT will feel justified in not implementing ASCs. 
Conversely, groups like SHEA and IHI who have already supported and recommended ASCs 




The Scandinavian Experience 
Many Scandinavian countries have been using ASCs and isolation for a number of years 
and they may be able to serve as a model in the absence of high quality studies or an RCT. The 
prevalence ofMRSA in Scandinavian countries is very low at only about 2%.45 Even more 
notably, the prevalence ofMRSA in the Netherlands has been as low as 0.5% in 1999.46 The 
Dutch attribute this infection control success to their "search and destroy" method. 
The Dutch Working Party Infection Prevention sets the guidelines for the control of 
MRSA in Dutch hospitals and it is largely centered on "search and destroy." All patients 
transferred from an outside facility are kept in quarantine in a single room with a negative 
pressure anteroom for at least two days until three serial cultures are negative for MRSA. 
Cultures are taken at one hour intervals after admission from the nose, throat, perineum, urine, 
sputum, and open wounds. All other patients directly admitted to the hospital are also screened 
serially three times at all of the sites mentioned above, but are not initially isolated. If one of 
these patients is colonized with MRSA, then they are moved to an isolation room. All other 
patients in the same original room must also be screened and put into isolation until it is proven 
that they are MRSA negative. Any involved health care workers are screened daily for MRSA. 
When two patients or one health care worker harboring MRSA is detected, the unit is closed to 
new admissions until the colonization/infection is treated.46 
Many European countries use active surveillance cultures and subsequent isolation to 
control MRSA cross-contamination; however, the above described method from the Netherlands 
is the most aggressive.46 It is unclear if such rigid treatment of patients and health care workers 
in the United States would be acceptable. 
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Additionally, it is unclear if the costs of a strict "search and destroy" program to the 
health care system and society in America would be acceptable or affordable. The University 
Medical Center Utrecht in the Netherlands retrospectively analyzed the costs of their "search and 
destroy" program over a ten year period from 1991 to 2000.47 Included in the study were costs 
associated with additional disposable materials, cultures, medication, decontamination of 
exposed items, and unit closures. Over the last decade, their "search and destroy" program cost 
about 2.8 million euros.47 Included in that value is the cost of2,265 lost hospitalization days and 
48 unit closures. Health care delivery and payment schemes are different in the United States 
and the Netherlands. The United States is also much larger and has many more hospitals and 
ICUs than the Netherlands. Setting the material costs aside, it is possible that losing thousands 
of hospital days across all of the hospitals in the United States could be overwhelming to health 
care financing. 
Remaining Concerns: Target Population for Screening 
Most of the included studies used high-risk groups to target their screening programs, but 
others used universal screening of all patients admitted to certain units. It is unclear what 
population should be screened. For example, Huang eta! showed that using ASCs to reduce the 
number ofMRSA infections among ICU patients actually reduced the MRSA infection rate in 
the remaining units of the hospital, which seems to indicate that targeted screening is sufficient.29 
However, Lucet eta! state in their hospital "only universal screening detected MRSA carriage 
with acceptable sensitivity. "24 
If it is determined that selective screening of high-risk patients is sufficient, then there 
must be a good definition of"high-risk." Warren et al published an epidemiological study 
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characterizing independent risk factors associated with MRSA colonization in patients admitted 
to a surgical ICU. 18 Of the 1,469 patients screened over a fifteen month period, 8% had nasal 
MRSA colonization. Risk factors for MRSA colonization at admission to the ICU included: 
1. Hospitalization in the past year 
• 1-2 admissions= aOR 2.60, 95%CI 1.47-4.60 
• >2 admissions= aOR 3.56, 95%CI 1.72-7.40 
2. Hospital stay >5 days prior to ICU admission 
• aOR 2.54, 95%CI 1.49-4.32 
3. Chronic obstructive pulmonary disease 
• aOR 2.16, 95%CI 1.17-3.96 
4. Diabetes mellitus 
• aOR 1.87, 95%CI 1.10-3.19 
5. Isolation ofMRSA in past six months 
• aOR 8.18, 95%CI 3.38-19.7918 
Used as a predictive test to identify patients with MRSA colonization, the presence of at 
least one of the above independent risk factors had a sensitivity of 89% and a specificity of 45%. 
The negative predictive value of this risk factor screening tool is 97%. 18 Therefore, a patient 
without any of the above risk factors can likely be ruled out as a possible MRSA carrier and does 
not need to have nasal swabs done for a microbiological culture. 
Only studies of adult ICU patients were included in this systematic review. Since the 
endemic levels ofMRSA are generally higher in ICUs than other hospital units, this entire group 
of acute patients could be considered high-risk. However, some of the authors of the articles 
included in this review only used a high-risk group within the ICU population for their studies 
assessing the role of ASCs.26• 28• 34 The three studies that used high-risk ICU subgroups defined 
patients with a known history ofMRSA infection or colonization and patients transferred from 
nursing homes as high-risk. One study also included patients with more than thirty days of 
hospitalization in an ICU or surgical ward.26 Another study included patients transferred from 
another hospital and patients who had had an operation within the last year. 34 The third study 
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had the broadest spectrum of high-risk patients and included patients transferred from hospitals 
where MRSA is endemic and patients requiring dialysis who also have a skin infection, patients 
receiving treatment that involves any kind of invasive device, and patients with pressure sores.28 
Remaining Concerns: Laboratory Methods 
Currently, there is no standard method for culturing and detecting MRSA across different 
clinical microbiology labs. Many labs use one of the numerous forms of selective incubation 
media, others use S. aureus identification tests and a methicillin susceptibility test, and some use 
direct identification tests via polymerase chain reaction (PCR).48 Even labs that use the same 
methods may have different experimental conditions such as the incubation temperature or salt 
concentration of the culture media. 48 The high level of variability in culturing method, time, and 
cost makes it difficult to assess each hospital's ability to accommodate increased demand for 
culturing if ASCs are implemented. 
Kunori et al developed a cost effectiveness model based in year 1999 English pounds to 
examine various laboratory screening approaches to detect MRSA.48 Based on details from a 
literature search, the British National Health Service costs database, and modeling with 
sensitivity analysis, they report that the most cost-effective screening method is to inoculate a 
single nasal sample directly onto ciprofloxacin Baird-Parker agar without the use of broth and 
then confirm the result with a staphylococcal latex test (ie, Pastorex Staph-Plus), but not with 
any methicillin-resistance test.48 This is valuable information for hospitals with labs that are 
unsure if they can afford an increased volume of MRSA samples for culture. 
However, some may argue that there are advantages to using rapid screening with PCR 
even though the start up costs and the costs of each test are high. Some hospitals may choose to 
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preemptively isolate patients until it is proven that they are negative for MRSA. With rapid 
testing, it is possible to rule out patients without MRSA more quickly, so the number of costly 
isolation days will decrease. More commonly, hospitals using ASCs wait to isolate patients until 
after they are identified as MRSA carriers. Rapid screening with PCR will reduce lag time by 
identifYing the positive patients who need to be isolated sooner, thereby increasing the 
effectiveness of the program. Notably, PCR was not used in any of the studies included in this 
review. The use of PCR for detecting MRSA is relatively rare and still being studied. 
Harbarth et al used quick, multiplex immunocapture-coupled PCR in the surgical and 
medical ICUs of their hospital in Switzerland and found that the median time from ICU 
admission to notification of test results decreased from 87 to 21 hours in the surgical ICU (p < 
0.001) and from 106 to 23 hours in the medical ICU (p < 0.001).49 The combined use of the 
quick screening method and preemptive isolation of all patients until a negative result was 
obtained was able to reduce the number of hospital-acquired MRSA infections in the medical 
ICU (RR 0.3, 95%CI 0.1-0.7), but not in the surgical ICU (RR 1.0, 95%CI 0.6-1.7).49 The 
results of this study are mixed, and it is hard to determine whether implementing PCR screening 
for MRSA will actually have an effect on patient outcomes in hospitals with different case 
m1xes. 
Remaining Concerns: Contact Precautions and the Psychological Effects oflsolation 
As previously mentioned, identification of MRSA carriers via ASCs is only a first step in 
potentially reducing MRSA infections. Depending on the hospital policy, patients are either 
isolated until it is proven that they are not colonized with MRSA or they are isolated once it has 
been shown that they are colonized. Either way, as asymptomatic patients are actively sought 
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out, the MRSA detection rate will increase and a greater number of patients will subsequently be 
put in isolation on contact precautions at some point during their hospitalization. 
Based on the studies included in .the review and the descriptions of the "search and 
destroy" method in Scandinavia, it is also unclear how contact precautions should be used in 
conjunction with ASCs. Stricter protocols may favor isolating all patients until they are proven 
negative for MRSA colonization. However, most of the included studies waited to receive the 
results from the cultures and then isolated the MRSA positive patients. There needs to be further 
investigation of the necessity of preemptive isolation, the additional costs of extra days on 
contact precautions, and a hospital's ability to shift to using mainly single rooms if preemptive 
isolation techniques are used. 
In addition to the increased financial burden to the hospital that comes with higher 
number of patients on isolation precautions, there are also patient-centered "costs" to isolation. 
Kirkland and Weinstein at Duke University report from a prospective observational study that 
health care workers treating ICU patients on contact precautions were about two times less likely 
to enter the room compared to health care workers taking care of ICU patients not on contact 
precautions. 5° Evans et al from University of Virginia report similar results. They found that 
isolated patients were visited 5.3 times/hour compared to 10.9 visits/hour for nonisolated patients 
(p<0.001).51 Additionally, despite more severe disease as designated by higher mean Acute 
Physiology and Chronic Health Evaluation II (APACHE II) scores among isolated patients (1 0.1 
± 1.0 vs 7.6 ± 0.8, P = .05), the overall contact time with health care workers was significantly 
less (29 ± 5 vs 37 ± 3 minlh, P = .008).51 It is unclear if the reduced level of contact with health 
care workers has an impact on patient outcomes. However, one small, prospective cohort study 
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does indicate that even after one week of isolation precautions, adult patients have worsening 
d . d . 52 epresswn an anxiety symptoms. 
Remaining Concerns: Efficacy ofDecolonization 
There is a systematic review maintained by the Cochrane Collaboration of all of the 
RCTs published from 1966 to 2003 that compare the effects of topical or systematic 
antimicrobials versus placebo on nasal and extra-nasal MRSA carriage, adverse events, and 
incidence of subsequent MRSA infections. 53 The conclusions drawn from the review of the six 
included randomized controlled trials are: 
"There is insufficient evidence to support use of topical or systemic 
antimicrobial therapy for eradicating MRSA. There is no demonstrated 
superiority of either topical or systemic therapy, or of combinations of 
topical and systemic agents. Potentially serious adverse events can arise 
from use of systemic agents. Topical or systemic agents can lead to the 
development of resistance to the antimicrobial agent used for 
eradication."53 
Although the literature, including many RCTs, does not support the use of topical or systemic 
medications for MRSA decolonization, almost half of the included studies used decolonization 
as part of their intervention program. Although in this case, the literature is sufficient and the 
results are clear, there is still variation in the use of decolonization as a part of an ASC program 
that illustrates the amount of uncertainty and confusion surrounding the subject. 
Remaining Concerns: Compliance 
Few of the studies included in this review reported levels of compliance with performing 
nasal swabs for the active surveillance of MRSA. It is unclear how thorough the screening must 
be to detect enough MRSA+ patients to make the program beneficial. 
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Additionally, the success of ASCs seems to hinge on the resultant actions that are taken 
such as isolation, contact precautions, and increased hygiene and cleaning that try to reduce the 
possibility of cross contamination. Unfortunately, healthcare workers' hands are the primary 
vehicle for cross contamination of patients in healthcare facilities.2 The 2002 Guideline for 
Hand Hygiene in Healthcare Settings included a review of thirty-four observational studies from 
1981-2000 that report an average of 40% (range 5-81 %) compliance with hand hygiene 
recommendations in health care facilities.54 One of the theories supporting contact precautions is 
that healthcare workers will be alerted to the presence of an infectious agent and will take the 
necessary precautions needed to avoid its spread. However, in an observational study at a large 
teaching hospital in Canada, the average compliance with all MRSA precautions was only 
28%.55 In particular, compliance with hand hygiene (either using alcohol rub or washing with 
soap and water) was 35% and the compliance with gowning and gloving was 65%.55 
An apparent advantage to using ASCs is that colonized patients who represent the 
reservoir from which MRSA can spread are identified and can be treated appropriately to reduce 
pathogenic transmission. However, the success of transmission reduction is largely based on the 
behavior and health care workers since their hands are currently the most common transmission 
vectors. With such poor levels of hand hygiene and contact precaution compliance, it is not 
certain that ASCs and contact precautions will be effective as their use becomes widespread 
across a variety of types of hospitals. It is unclear what level of compliance with hand hygiene 
and other infection control practices there must be for ASCs to be useful. 
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Limitations of this review 
All of the components of the search were limited to English, which may present some 
bias as there may be many researchers who do not speak English as a first language and who 
have published relevant studies in a non-English journal. However, this bias is likely minimal 
because there are a great number of studies published in English by researchers from non-
English speaking countries that have been included in this review. 
As with all systematic reviews of published literature, publication bias may be affecting 
this review. Publication bias is of particular concern in this review because of the large number 
of poor quality studies. Studies with negative findings, especially those with moderate or poor 
quality, are not as likely to be published, and it is possible that the preponderance of studies 
supporting ASCs present a falsely inflated positive evidence base. 
Additionally, the quality assessment and data abstraction components of this systematic 




Observational evidence favors the use of ASCs, but the overall quality is so low that 
definitive, evidence-based recommendations cannot be made. This review identified many gaps 
within the literature, including a need for a clear definition of ASCs, a clear implementation 
protocol that includes a defined screening group and laboratory methods, and rigorous economic 
evaluations. Considering the paucity of high quality information and the uncertainty concerning 
ASCs, it is not surprising that there is no general consensus about active MRSA screening among 
infection control experts. 
It is surprising that highly respected professional organizations such as SHEA and IHI 
have strongly recommended using ASCs in their most recent guidelines without having a strong 
scientific foundation to support them. However, making recommendations for clinical practice 
often involves issues outside of basic scientific proof. For example, patient or societal 
expectations, legal concerns, ethical considerations, and the desire to use novel concepts for 
quality improvement may also be driving the decision to support ASCs. Considering these 
factors along with the need to reduce a large public health problem, the generally positive results 
supporting ASCs, and the great success of the "search and destroy" method in Scandinavia, it is 
understandable that these organizations favor the implementation ofMRSA screening in 
hospitals across the United States. 
A randomized, controlled trial to prove the utility of ASCs has been called for, but may 
not be a good use oflimited research funds. Instead, it may be better to accept the imperfect 
evidence that demonstrates the usefulness of ASCs in reducing MRSA infections and MRSA-
related costs, and to focus further research on defining the details (risk assessment, lower-cost 




Evidence Rating Criteria for Observational Studies19 
One point was given for each "yes" answer. Controlled observational studies that meet 
80% or more of the criteria are rated as high, 40-79% are rated as moderate, and less than 40% 
are rated as poor. Studies that do not include a control group cannot be rated "high." 
Uncontrolled observational studies that meet 80% of the criteria are rated as moderate, and those 
that meet less than 80% are rated as low. 
COHORT STUDY 
Quality Criterion Yes No 
~~·there sufficient description of the groups and the 
stribution of prognostic factors? 
Is the intervention sufficientlydescribed? 
Were the groups comparable on all important 
onfounding factors or were appropriate 
adjustments made? 
Was the outcome assessment masked to exposure 
latus? 
Was the follow-up long enough for outcomes to 
pccur? 
Did a reasonable proportion of the cohort follow-up? 
~ere the drop out rates and reason similar across 
groups? 
[cASE-CONTROL STUDY 
Quality Criterion Yes No 
s the case definition explicit? 
~ere the controls randomly selected from the 
~ource population? 
How comparable are the groups with respect to 
~onfounders? 
~as the intervention assessed the same way for 
both groups? 
f/vas the response rate well defined? 
~ere reasons for non-response similar in both 
groups? 
Was an appropriate statistical analysis used? 
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BEFORE AFTER STUDY 
Quality Criterion rres No 
~e baseline characteristics measured? 
Was there a power calculation? 
Were possible confounders reported? 
Was there Qood intervention inteQrity? 
Was there protection against contamination or 
ascertainment that intervention was independent of other 
interventions? 
Were outcomes measured appropriately and consistently 
hroughout the study period? 
Evidence Rating Criteria for Economic Analyses19• 20 
One point was given for each "yes" answer. Studies with 80% or higher are rated as 
high, 40-79% are rated as moderate, and less than 40% are rated as poor. 
COST BENEFIT ANALYSIS 
Quality Criterion rres No 
Is there a well defined question? 
Are all important and relevant costs and outcomes for 
each alternative identified? 
Is the study conducted from the societal perspective? 
Is the time horizon clinically appropriate and relevant to 
he study question? 
Are key harms included? 
Is the best available evidence used to estimate 
~ffectiveness? 
f'\re costs and outcomes appropriately valued? 
Kpublished data, microcostinQ, author estimate?) 
Do effect measures capture preferences or utilities? 
~re costs and outcomes adjusted for differential timing? 
~re appropriate sensitivity analyses performed? 
V\re the results Qeneralizable? 
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Appendix B. Evidence Table 
Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Ratin!:l 
Detection of MRSA infections 
Unreported culturing method. increased by 30-135% with 
ASCs. Incidence density 
Huang SS, et ASCs at admission, then increased from a mean of 
a/." Retrospective United 8013 ICU patients in weekly. Contact precautions if 6.7 to 8.9 cases per 1000 
2007 cohort States 12 different ICUs MRSA+. patient-days. Moderate 
12% importation Unreported culturing method. 
Huang SS, et Retrospective rate into ICU. Decreased incidence of HA-
a/. 29 interrupted time United ASCs at ICU admission, then MRSA bacteremia by 75% in 
2006 series States 6000 ICU patients weekly. ICU and 40% in non-ICU. Moderate 
Standard culturing method. 
ASCs, isolation, and 
ASCs at admission, contact decolonization program 
precautions if MRSA+. Topical reduced MRSA incidence by 
Gould IM, et nasal antimicrobial and 11.4% (from about 15% to 
al." Interrupted time chlorhexidine baths for MRSA+ 5%). Screening 11 patients 
2006 series Scotland ICU patients and MRSA-. will prevent 1 case of MRSA. Moderate 
Unreported culturing method. 
ASCs of high-risk patients at 
admission. Contact precautions, 
therapeutic baths from 
Wernitz MH, et admission until proven MRSA-. Based on expected trend 
al." Interrupted time 73, 080 patients Contact precautions and estimates, HA-MRSA 
2005 series Germany admitted to all units decolonization if MRSA+. infections decreased 48%. Moderate 
Decreased incidence of 
MRSA infection by 14% (5.6 
4% importation rate cases to 1.4 cases/1 00 
into ICU. Unreported culturing method. admissions). 
54 MICU patients ASCs at admission, then Screening is cost effective if 
Chaix C, et a/22 with and without weekly. Contact precautions if prevalence at admission 




Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Rating 
Decreased incidence of 
MRSA infections from 8.2% 
Unreported culturing method. to 2.8% over 5 years, 
p=0.001. Decreased 
ASCs of all patients at incidence of infection from 
Sandri AM, et admission to ICU and weekly any Staphylococcus strain 
a/.36 Prospective thereafter. Decolonization for from 9.9% to 3.4% over 5 
2006 ecological Brazil 2200 ICU patients MRSA+ patients. years, p=0.001. Low 
Standard culturing method. 
ASCs at admission to ICU, then Decreased incidence of 
Shitrit P, et a/.30 Interrupted time 
weekly. Contact precautions MRSA bacteremia by 50% 
and decolonization for MRSA+ (0.74 to 0.37 cases/1000 
2006 series Israel High-risk patients patients. admissions) Low 
No change in incidence of 
MRSA infections in one 
hospital (from 0. 73 to 0.57 
cases/1 000 pt-days, p=0.35). 
Decrease in incidence of 
MRSA infection in a second 
hospital (from 0. 76 to 0.45 
cases/1 000 pt-days, p=0.05). 
Combined costs of ASCs and 
isolation at both hospitals = 
$52594.62/yr. Prevented 
Interrupted time Standard culturing method. estimated 6 cases of MRSA 
series with per year that would have cost 
cost- ASCs at admission, then every $275520/yr. Total cost 
West TE, et a/. 31 effectiveness United 7714 high-risk Monday. Contact precautions if savings of ASC program = 
2006 analysis States patients MRSA+. $222925.38/yr. Low 
43 
McGinigle 
Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Rating 
Decreased incidence of 
MRSA infection by 58% over 
all interventions. 
Standard culturing method. Acquired MRSA/1 00 days 
decreased from 10% initially 
ASCs at admission of ICU to 9% after ASC in ICU, to 
patients, then ICU+ other high- 3.8% with ASCs in ICU + 
Eveillard M, et 1% importation rate risk pts, then ICU + other high- high-risk patients, to 3.1% 
a/.56 Before and risk pts + automatic alert with ASCs in ICU + high-risk 
2005 after series France 8506 inpatients system !patients + automatic alert Low 
Standard culturing method. 
Lucet JC, et ASCs at admission, then Decreased incidence of 
a!.'? Prospective weekly. Contact precautions for MRSA infection from 7.0% to 
2005 ecological France 8548 ICU patients MRSA+. 2.8%. Low 
No change in importation rate 
of colonized MRSA to the 
I CU. 
No cross contamination of 
MSSA or MRSA over 3 
months (as detected by daily 
cultures). 
Standard culturing method. 
5. 7% importation ASC + isolation would have 
Nijssen S, et Prospective rate ASCs at admission and daily appeared successful, but 
a/.38 ecological United thereafter (no reporting of would have been falsely 
2005 study States 158 MICU patients __ results or contact precautions) positive Low 
44 
McGinigle 
Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Rating 
Decreased incidence of 
Standard culturing method. MRSA bacteremia by 42% 
(0.64 to 0.37 cases/1 000 
ASCs at admission, then every admissions). 
Pan A, et a/. 33 
3 days. Contact precautions 
Before and and decolonization for all RR 0.57 (95%CI 0.35-0.92), p 
2005 After Italy All admitted patients MRSA+. = 0.03 Low 
Screening decreased 
incidence of M RSA 
infections. 
Rate decreased from 9.2 to 
6.6 cases/1000 pt-days, then 
Standard culturing method. increased to 11.6 cases/1 000 
pi-days when ASC 
ASCs at admission, then compliance dropped to 68%. 
Troche G, et Prospective weekly and at discharge. With better compliance, 
a/.39 ecological United Contact precautions and incidence at end of study was 
2005 study States 2235 ICU patients decolonization if MRSA+. 5.6 cases/1 000 pt-days. Low 
No change in incidence of 
MRSA infection (5.0% over 
course of study) 
Standard culturing method. No significant difference in 
8. 7% importation mortality in colonized vs. 
Thom~son OS, rate into ICU ASCs at admission to ICU, then infected patients (31.7% 
et a/4 Prospective weekly. Contact precautions (95%CI 24.9- 38.9) vs. 
2004 ecoloqical Enqland 1252 ICU patients and decolonization if MRSA+. 58.8%(95%CI 35.4- 81.2). Low 
Standard culturing method. 
Decreased incidence of 
ASCs of high-risk patients at MRSA infections from 4.0 to 
admission, contact precautions 0.4 cases/1000 pt-days. 
and decolonization for MRSA+ 
Tomic V, et a/. 34 
patients, introduction of alcohol Decreased proportion of 
Before and hand rub, continuous hygiene acquired MRSA cases 50% 
2004 after Slovenia 33905 inpatients education to 6.1°f<,(p<0.001 for trend) Low 
45 
McGinigle 
Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Rating 
Decreased incidence of 
Standard culturing method. MRSA infection from 5.2% to 
1.7%, p=0.018 (4.0 to 2.2 
ASCs at admission, then cases/1000 pt-days.) 
weekly and at discharge. 
Contact isolation and No significant change in 
Souweine B, et decolonization if MRSA+. Twice mortality attributable to 
a/.'5 Before and weekly reminders to reinforce MRSA infection (from 50% to 
2000 after France 584 ICU patients intervention. 62.5%, p=0.48). Low 
High-risk screening and 
isolation prevented 35 (48%) 
of expected cases for a net 
savings of 110236 euros/yr. 
Unknown culturing method. Program cost effective if 
prevent 3 MRSA infections/yr. 
Wernitz MH, el ASCs at admission, preemptive Screening universally is cost 
a/. 23 Cost-benefit 529 high-risk isolation and therapeutic baths effective if 22% of screened 
2005 analysis Germany patients until proven MRSA- !patients are MRSA+ Moderate 
Universal screening is more 
beneficial than alternative 
high-risk screening. ASCs of 
4.4% importation all patients admitted to the 
Lucet JC, et rate into ICU Standard culturing method. ICU and preventive isolation 
a/.24 Cost-benefit is cost effective if importation 
2003 analysis France 2189 ICU patients ASCs at ICU admission rate is >1 %. Moderate 
ASC program economically 
·ustified if it can prevent 4 
MRSA infections. 
Unknown culturing method. 49.95 euros to screen each 
Gavalda L, et high-risk patient vs. 2730 
812, Cost I; proactive program to screen euros to treat MRSA 
2006 comparison Spain 251 patients high-risk patients" infection. Low 
46 
McGinigle 
Author, Sample Evidence 
Year Study Design Location Characteristics Intervention Summary of Results Rating 
Cost of ASC and 
management of colonized 
patients is 45% of the total 
costs attributed to MRSA. 
Cost of treating MRSA 
infections= 143,600 
Canadian dollars/yr 
Costs of ASCs = 54906.50/yr 
and 
Standard culturing method. costs of managing colonized 
Kim T, et a/25 
4% importation rate patients= 64047.50/yr. 
Cost ASCs of high-risk patients at Total for preventive program 
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